Diffuse Bone Marrow Uptake on Whole-Body F-18 Fluorodeoxyglucose Positron Emission Tomography in a Patient Taking Recombinant Erythropoietin

F-18 fluorodeoxyglucose (FDG)–positron emission tomography (PET) is used extensively in oncology to diagnose, stage, and restage patients with various malignancies. Many patients treated for malignancies develop neutropenia secondary to marrow suppressive chemotherapy and are subsequently treated wi...

Full description

Saved in:
Bibliographic Details
Published in:Clinical nuclear medicine 2004-03, Vol.29 (3), p.161-163
Main Authors: Blodgett, Todd M., Ames, Jennifer T., Torok, Frank S., McCook, Barry M., Meltzer, Carolyn C.
Format: Article
Language:English
Subjects:
Aged
Bone Marrow - diagnostic imaging
Bone Marrow - drug effects
Bone Marrow - metabolism
Bone Marrow Neoplasms - diagnosis
Bone Marrow Neoplasms - diagnostic imaging
Colorectal Neoplasms - diagnosis
Colorectal Neoplasms - diagnostic imaging
Colorectal Neoplasms - drug therapy
Diagnosis, Differential
Erythropoietin - administration & dosage
Fluorodeoxyglucose F18 - pharmacokinetics
Humans
Radiopharmaceuticals - pharmacokinetics
Recombinant Proteins
Tomography, Emission-Computed - methods
Whole-Body Counting - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:F-18 fluorodeoxyglucose (FDG)–positron emission tomography (PET) is used extensively in oncology to diagnose, stage, and restage patients with various malignancies. Many patients treated for malignancies develop neutropenia secondary to marrow suppressive chemotherapy and are subsequently treated with synthetic hematopoietic growth factors (HGF), both granulocyte–macrophage colony-stimulating factor (GM-CSF) and granulocyte–colony-stimulating factor (G-CSF). Patients taking HGF can present a diagnostic challenge for those interpreting PET because they can demonstrate diffuse marrow uptake on FDG-PET scans, mimicking diffuse bone marrow metastases. It has not been reported whether bone marrow uptake is affected on PET scans in patients taking erythropoietin, the erythroid-specific cell-line stimulator. We report a case of extensive diffuse bone marrow uptake in a 77-year-old man with a history of colon cancer who began taking erythropoietin 3 weeks before his PET scan. This case demonstrates the need to consider erythropoietin in the differential diagnosis of possible etiologies causing diffuse bone marrow uptake on PET scans.
ISSN:0363-9762
DOI:10.1097/01.rlu.0000115654.90324.02